Clarus Therapeutics Holdings, Inc. Warrants
CRXTW
CRXTW was delisted on the 30th of August, 2022.
16 hedge funds and large institutions have $512K invested in Clarus Therapeutics Holdings, Inc. Warrants in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 5 closing their positions.
16% less funds holding
Funds holding: 19 → 16 (-3)
47% less capital invested
Capital invested by funds: $966K → $512K (-$454K)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$5.89K |
| 2 |
MSU
Mizuho Securities USA
New York
|
+$4.54K |
| 3 |
VF
Virtu Financial
New York
|
+$2.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
-$42K |
| 2 |
ICMH
Integrity Capital Management (HK)
Central,
Hong Kong
|
-$20K |
| 3 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$19K |
| 4 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
-$10K |
| 5 |
CCM
Context Capital Management
Lajolla,
California
|
-$4.54K |
CRXTW Hedge Fund Activity: Q1 2022 in Review
16 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) for Q1 2022, worth a combined $512K — down 47% from $966K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CRXTW and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was Warberg Asset Management, adding an estimated $5.89K. The largest seller was Privium Fund Management, exiting entirely with an estimated $42K sold.
- 16 institutional investors held Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) as of Q1 2022, down from 19 in Q4 2021.
- Funds reported $512K of Clarus Therapeutics Holdings, Inc. Warrants stock for Q1 2022, down 47% quarter-over-quarter.
- 2 funds opened new Clarus Therapeutics Holdings, Inc. Warrants positions in Q1 2022 and 5 closed out, a net change of -3 holders.
- The largest Clarus Therapeutics Holdings, Inc. Warrants buyer in Q1 2022 was Warberg Asset Management, an estimated $5.89K added.
- The largest Clarus Therapeutics Holdings, Inc. Warrants seller in Q1 2022 was Privium Fund Management, an estimated $42K sold.
Based on aggregated 13F filings for Q1 2022.